GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...

GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

(Alliance News) - GSK PLC on Friday reported that its Nucala treatment has been approved in China to treat long-term sufferers of a sinus ailment following a phase 3 study.

Jiangxi Shanxiang Pharmaceutical's first generic "Sorafenib" is about to be approved The results of Fujian's centralized procurement of medical consumables are announced, and Johnson & Johnson and ...

INR:9705. bangladesh sri lanka cricket match GlaxoSmithKline's "Mepolizumab" is approved for listing in China Has Hisun recovered? Earned 240 m ...

INR:7444. bharat rummy circle GlaxoSmithKline's "Mepolizumab" is approved for listing in China Pharmaceutical and Health Industry Weekly Report (June 1st - Ju ...

INR:7584. 2024–25 saudi pro league GlaxoSmithKline's "Mepolizumab" is approved for listing in China 10,000 yuan allowance, job subsidies, increased m ...